BigHat is thrilled to announce the successful completion of our strategic collaboration with Johnson & Johnson* focused on leveraging our integrated machine learning platform to design novel and challenging antibodies. 

The next stage of development includes advancing multiple novel sequences with an aim to producing impactful medicines and therapies for patients in the neuroscience therapeutic area. 

“This successful collaboration is an example of the power of BigHat’s Milliner platform, which integrates a high-speed, automated wet lab with fit-for-purpose machine learning models, to unlock novel, next-generation antibody therapeutics. We look forward to continuing to create next-gen antibodies for patients in need.” - Peyton Greenside, CEO & Co-founder of BigHat Biosciences.‍

*Legal entity: Janssen Biotech, Inc.

‍